



Satiate Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cefixime Tablet IP 200 mg	AR No.	: SA/GO-181225/004
Batch No.	: 0131	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.	
Average weight	: 293.65 mg	
Uniformity of weight	: Min Max -1.51 % +2.67 %	Limit ±5.0 % of average weight
Identification Test (By HPLC)	: Complies	To comply
Water	: 5.12 %	NMT 10.0 %
Dissolution Test (By UV)	: Min Max Avg	Limit
In Phosphate buffer pH 7.2	: 90.25 % 95.29 % 93.27 %	Q. NLT 75.00 %
Leak test	: Complies	To comply
Hardness	: 3.5 kg/cm ²	

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By HPLC) :-				
Composition				
Each film coated tablet contains:-				
Cefixime IP (As trihydrate)				
Eq. to anhydrous Cefixime	199.47 mg	200.00 mg	(180.00 - 220.00) mg	IP 2022

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Surender Panghal
Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiatate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Telmisartan Tablet IP 40 mg	AR No.	: SA/GO-181225/005
Batch No.	: 2508172	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024/Amendment List-07	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: White circular shaped biconvex uncoated tablet plain surface on both sides.	
Average weight	: 222.58 mg	
Uniformity of weight	: Min Max -1.15 % +2.18 %	Limit ±7.5 % of average weight
Identification Test (By HPLC)	: Complies	To comply
Hardness	: 3.0 kg/cm2	
Leak test	: Complies	To comply
Friability	: 0.12 %	NMT 1.0 %
Related substances (By HPLC)	:	
Any secondary impurity	: Not detected	NMT 0.2 %
Dissolution Test (By UV)	: Min Max Avg	Limit
In phosphate buffer (pH 7.5)	: 90.65 % 95.72 % 93.82 %	Q. NLT 75.00 %
Uniformity of content	: 95.18 % 100.32 % 98.82 %	
Acceptance value	: 3.8	NMT 15.0

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay	-	-	-	-
Composition				
Each uncoated tablet contains:-				
Telmisartan IP	39.53 mg	40.00 mg	(36.00 - 44.00) mg	IP 2022 & IP Addendum 2024/Amendment List-07

Disclaimer :

Satiatate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Telmisartan Tablet IP 40 mg	AR No.	: SA/GO-181225/005
Batch No.	: 2508172	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024/Amendment List-07	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Panghal
Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiatresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Prednisolone Tablets IP 10mg	AR No.	: SA/GO-181225/006
Batch No.	: ACT10-239	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity.	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024	Date of Issue of the report	: 25/12/2025

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>
Description	: White circular shaped biconvex uncoated tablets plain on both sides.	
Average weight	: 101.67 mg	
Uniformity of weight	: Min Max -1.25 % +2.51 %	Limit ±7.5 % of average weight
Identification Test	:	
A - By IR	: Complies	To comply
B - By HPLC	: Complies	To comply
Uniformity of content	: Min Max Avg 96.56 % 101.42 % 99.48 %	
Acceptanc value	: 3.8	NMT 15.0
Dissolution test (By UV)	: Min Max Avg	Limit
In water	: 90.48 % 95.56 % 93.42 %	Q.NLT 70.00 %
Related substances (By HPLC)	:	
Any secondary impurity	: 0.12 %	NMT 1.00 %
Sum of all the impurities	: 0.12 %	NMT 3.00 %
Leak test	: Complies	To comply
Hardness	: 2.5 kg/cm2	
Friability	: 0.11 %	NMT 1.0 %

<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>	<u>LIMITS</u>	<u>METHOD</u>
Assay (By HPLC) :-				
Composition				
Each uncoated tablet contains :-				
Prednisolone IP	9.95 mg	10.00 mg	(9.00 - 11.00) mg	IP 2022

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client,only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Prednisolone Tablets IP 10mg	AR No.	: SA/GO-181225/006
Batch No.	: ACT10-239	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Carboxymethyl Cellulose Sodium Eye Drops	AR No.	: SA/GO-181225/007
	: IP 0.5% w/v	Batch Size	: NM
Batch No.	: 1225056	D/E	: 08/2027
D/M	: 09/2025	Name of supplier	: NM
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 15 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample received on	: 18/12/2025
Date of receipt	: 17/11/2025	Date of completion of analysis	: 01/01/2026
Date of start of analysis	: 18/12/2025	Date of Issue of the report	: 01/01/2026
Protocol of test applied	: IP Addendum 2024 & Amendment list 07		

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Clear colourless liquid filled in green coloured plastic vial.	
Identification Test	:	
A- By Chemically	: Complies	To comply
B- By UV	: Complies	To comply
Appearance of solution	:	
i) Clarity of solution	: Complies	To comply
II) Colour of solution	: Complies	To comply
pH	: 7.452	(6.00 - 8.00)
Nominal volume	: 10.0 ml	
Uniformity of filled volume	: Min Max 10.2 ml 10.6 ml	Limit NLT 9.0 ml
Osmolality	: 295.5 mOsmol/L	(270.00 - 350.00) mOsmol/Kg
Sterility	: Complies	To comply
Leak Test	: Complies	To comply

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay :- (By UV)				
Composition				
Carboxymethyl cellulose sodium IP	0.499 % w/v	0.50 % w/v	(0.475 - 0.575) % w/v	IP Addendum 2024/Amendment List-07

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Carboxymethyl Cellulose Sodium Eye Drops	AR No.	: SA/GO-181225/007
	IP 0.5% w/v	Batch Size	: NM
Batch No.	: 1225056	D/E	: 08/2027
D/M	: 09/2025	Name of supplier	: NM
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 15 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample received on	: 18/12/2025
Date of receipt	: 17/11/2025	Date of completion of analysis	: 01/01/2026
Date of start of analysis	: 18/12/2025	Date of Issue of the report	: 01/01/2026
Protocol of test applied	: IP Addendum 2024 & Amendment list 07		

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 01/01/2026


Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiatresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Spironolactone Tablets IP 25 mg	AR No.	: SA/GO-181225/008
Batch No.	: T250920	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS		
Description	: White circular shaped flat uncoated tablet having scored line on one side and plain on other side.			
Average weight	: 180.12 mg			
Uniformity of weight	: Min Max -1.21 % +2.15 %	Limit ±7.5 % of average weight		
Identification Test	:			
A-By IR	: Complies	To comply		
B-By TLC	: Complies	To comply		
C-By Chemical test	: Complies	To comply		
Dissolution test (By UV)	: Min Max Avg 90.18 % 95.36 % 93.42 %	Limit Q. NLT 70.00 %		
Uniformity of content	: 95.27 % 100.32 % 98.29 %			
Acceptance value	: 3.8	NMT 15.0		
Related substances (By HPLC)	:			
Sum of all secondary impurities (Other than canrenone)	: 0.12 %	NMT 1.00 %		
Canrenone	: 0.15 %	NMT 1.00 %		
Total impurities	: 0.27 %	NMT 1.00 %		
Leak test	: Complies	To comply		
Hardnes	: 3.5 kg/cm ²			
Friability	: 0.15 %	NMT 1.0 %		
CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By UV) :-				
Each uncoated tablet contains:-				
Spironolactone IP	24.57 mg	25.00 mg	(23.75 - 26.25) mg	IP 2022

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Spironolactone Tablets IP 25 mg	AR No.	: SA/GO-181225/008
Batch No.	: T250920	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that, the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiata

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Mupirocin Ointment IP 2 % w/w	AR No.	: SA/GO-181225/009
Batch No.	: 2501348	Batch Size	: NM
D/M	: 01/2025	D/E	: 12/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 12 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 24/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Colourless semi solid mass filled in printed laminated tube.	
Nominal weight	: 5.00 g	
Uniformity of fill. weight	: Min. Max 5.02 g 5.12 g	Limit NLT 4.5 g
Identification Test	:	
A-By TLC	: Complies	To comply
B-By HPLC	: Complies	To comply
Related substances (By HPLC)	:	
Mupirocin Impurity C3	: 0.58 %	NMT 4.00 %
Mupirocin Impurity D1	: 0.69 %	NMT 5.00 %
Mupirocin Impurity E2	: 1.65 %	NMT 10.00 %
Any other secondary impurity	: 0.15 %	NMT 1.50 %
Sum of all secondary impurities	: 3.07 %	NMT 20.00 %

CONTENTS	OBTAINED	CLAIM	LIMITS
Assay (By HPLC) :-			
Composition :-			
Mupirocin IP	1.99 % w/w	2.00 % w/w	(1.80 - 2.30) % w/w

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 24/12/2025

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiata Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiatresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Trypsin and Chymotrypsin (1:6) Tablets 100K AU	AR No.	: SA/GO-181225/010
Batch No.	: GAET25010	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 80 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Brick red coloured circular shaped biconvex enteric coated tablet plain surface on both sides.	
Average weight	: 147.12 mg	
Uniformity of weight	: Min Max -1.42 % +2.57 %	Limit ±7.5 % of average weight
Identification Test (By UV)	: Complies	To comply
Colour Identification	: Complies	To comply
Disintegration Time	:	
In 0.1 M HCl acid	: Not break	Should not break in 120 Min.
In phosphate buffer pH 6.8	: 23 Min 28 Sec.	NMT 60.0 Min.
Leak test	: Complies	To comply
Hardness	: 3.5 kg/cm2	

CONTENTS	OBTAINED	CLAIM	LIMITS
Assay :			
Each enteric coated tablet contains			
100,000 Amour units trypsin chymotrypsin of enzymatic activity	102570.00 IU	100,000.00 IU	NLT 90,000.0 IU
Supplied by a purified concentrate which has			
Specified trypsin & chymotrypsin activity in the ratio of			
Approximately six to one			

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Trypsin and Chymotrypsin (1:6) Tablets 100K AU	AR No.	: SA/GO-181225/010
Batch No.	: GAET25010	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 80 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report




Date : 25/12/2025


 Person In-charge of Testing
 Dr Surender Panghal (M.Pharm, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiatresearch@gmail.com, Website : www.sralabs.com

TEST REPORT



FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Methylcobalamin Injection 500mcg	AR No.	: SA/GO-181225/011
Batch No.	: D31Y017	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 02/01/2026

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>	
Description	: Red coloured liquid filled in amber coloured glass ampoule.		
Identification test	: Complies	To comply	
pH	: 4.751		
Nominal volume	: 1.0 ml		
Extractable volume	: 1.1 ml	NLT 1.0 ml	
Particulate Matter	:		
Greater than or Equal to 10 µm	: 265 Particles/Container	NMT 6000 Particles/Container	
Greater than or Equal to 25 µm	: 55 Particles/Container	NMT 600 Particles/Container	
Sterility	: Complies	To comply	
Leak Test	: Complies	To comply	
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>	<u>LIMITS</u>
Assay			
Composition			
Each ml contains			
Methylcobalamin IP	512.25 mcg	500.00 mcg	(450.00 - 550.00) mcg

- Note:-**
- 1.The result listed refers only to the tested samples & applicable parameters; endorsement of products is neither inferred nor implied.
 - 2.Total liability of our institute is limited to the invoiced amount
 - 3.This report is not to be reproduced wholly or in part and cannot be used as evidence in the court of law and should not be used in any advertising media without our special permission in writing.
 - 4.Sample drawn and submitted by the party for Analysis unless otherwise stated.
 - 5.Party has asked for the above tests only.

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL-ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: sатиateresearch@gmail.com, Website : www.sralabs.com

TEST REPORT



FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Methylcobalamin Injection 500mcg	AR No.	: SA/GO-181225/011
Batch No.	: D31Y017	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 02/01/2026

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 02/01/2026


Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

- Note:-**
- 1.The result listed refers only to the tested samples & applicable parameters; endorsement of products is neither inferred nor implied.
 - 2.Total liability of our institute is limited to the invoiced amount
 - 3.This report is not to be reproduced wholly or in part and cannot be used as evidence in the court of law and should not be used in any advertising media without our special permission in writing.
 - 4.Sample drawn and submitted by the party for Analysis unless otherwise stated.
 - 5.Party has asked for the above tests only.

Page : 2 of 2

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com

TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of Sample	: Diclofenac Diethylamine 1.16 % w/w, Linseed Oil 3%, w/w Methyl Salicylate 10 % w/w and Menthol 5 % w/w Spray	AR. No.	: SA/GO-181225/012
Batch No.	: W250120	Batch size	: NM
D/M	: 08/2025	D/E	: 07/2028
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test req. Slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti toThirumurugan Poondi Ring Road Tiruppur-641603	Sample quantity	: 03 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start analysis	: 18/12/2025	Date of completion of analysis	: 21/12/2025
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 23/12/2025

Description	Colourless liquid filled in printed aluminium container.	
Identification Test (By HPLC)		
A- Diclofenac Diethylamine	Complies	To comply
B- Menthol & Methyl Salicylate	Complies	To comply
C- Linseed Oil	Complies	To comply
Nominal weight	142.00 g	
Extractable weight	142.5 g	NLT 142.00 g
Can pressure @ 25°C	39.12 pSi°	NLT 35 pSi°
Delivery rate @ 25°C	0.870 g/sec.	(0.300 – 1.500) g/sec
Leak test	Complies	To comply

<u>TEST PARAMETERS</u>	<u>RESULT</u>	<u>CLAIM</u>	<u>LIMIT</u>
Assay:-			
Composition			
Diclofenac Diethylamine IP (1.16 % w/w)			
Eq. to Diclofenac Sodium IP	0.987 % w/w	1.00 % w/w	(0.90 – 1.100) % w/w
Virgin Linseed Oil BP	2.98 % w/w	3.00 % w/w	(2.70 – 3.30) % w/w
Methyl Salicylate IP	9.89 % w/w	10.00 % w/w	(9.00 – 11.00) % w/w
Menthol IP	4.97 % w/w	5.00 % w/w	(4.50 – 6.00) % w/w

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Surender Panghal

Person-in charge of testing
Dr Surender Panghal (M. Pharma, Ph.D.)
(Quality Manager)

Date : 23/12/2025

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cilnidipine Tablets IP 10 mg	AR No.	: SA/GO-181225/013
Batch No.	: WCB25012G	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.	
Average weight	: 136.95 mg	
Uniformity of weight	: Min Max -1.32 % +2.51 %	Limit ± 7.5 % of average weight
Identification Test (By HPLC)	: Complies	To comply
Dissolution Test (By UV)	: Min Max Avg 90.56 % 95.88 % 93.82 %	Limit Q. NLT 70.00 %
Uniformity of content	: 96.52 % 101.56 % 99.48 %	
Acceptance value	: 3.9	NMT 15.0
Related Substances (By HPLC)	:	
Any secondary impurity	: Not detected	NMT 0.5 %
Sum of all secondary impurities	: Not detected	NMT 1.0 %
Leak Test	: Complies	To comply
Hardness	: 2.5 kg/cm2	

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By HPLC)				
Composition				
Each film coated tablet contains				
Cilnidipine IP	9.95 mg	10.00 mg	(9.00 - 11.00) mg	IP 2022

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiata

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cilnidipine Tablets IP 10 mg	AR No.	: SA/GO-181225/013
Batch No.	: WCB25012G	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Surender Panghal
Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiata Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiata

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Paracetamol 162.5mg and Tramadol 18.75mg	AR No.	: SA/GO-181225/014
Batch No.	: AR2TF01	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP Addendum 2024	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED	LIMITS		
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.	To comply		
Identification Test (By HPLC)	: Complies	To comply		
Average weight	: 258.17 mg			
Uniformity of weight	: Min Max -1.25 % +2.61 %	Limit ±5.0 % of average weight		
Dissolution Test (By HPLC)	: Min Max Avg	Limit		
0.1 M HCl Acid	:			
For Paracetamol	: 90.56 % 95.42 % 93.65 %	Q. NLT 80.00 %		
For Tramadol HCl	: 91.42 % 96.66 % 94.72 %	Q. NLT 80.00 %		
4-Aminophenol (By HPLC)	: Not detected	NMT 0.15 %		
Related substances (By HPLC)	:			
O -Desmethyl - tramadol	: Not detected	NMT 0.2 %		
Tramadol compound A	: Not detected	NMT 0.2 %		
Any other secondary impurities	: Not detected	NMT 0.2 %		
Sum of all secondary impurities	: Not detected	NMT 0.8 %		
Uniformity of content	: Min Max Avg			
For-Tramadol	: 96.56 % 101.48 % 99.58 %			
Acceptance value	: 3.8	NMT 15.0		
Leak test	: Complies	To comply		
Hardness	: 3.5 kg/cm2			
CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By HPLC)	:			
Each film coated tablet contains				
Paracetamol IP	160.16 mg	162.50 mg	(146.25 - 178.75) mg	IP Addendum

Disclaimer :

Satiata Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Bahwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Paracetamol 162.5mg and Tramadol 18.75mg Tablet	AR No.	: SA/GO-181225/014
Batch No.	: AR2TF01	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP Addendum 2024	Date of Issue of the report	: 25/12/2025

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Tramadol HCl IP	18.67 mg	18.75 mg	(16.88 - 20.63) mg	2024 IP Addendum 2024

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Iron sucrose injection USP	AR No.	: SA/GO-181225/015
Batch No.	: MPJ253642	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: USP	Date of Issue of the report	: 01/01/2026

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Brown coloured liquid filled in amber coloured glass ampoule.	
Identification Test	:	
Identification A -Iron	: Complies	
Identification B -Sucrose	: Complies	
Identification C	:	
Molecular weight Determination (MW/MN)	:	
MW	: 47113.46 Da	(34000 - 60000) Da
MN	: 36241.12 Da	NLT 24000 Da
MW/MN	: 1.3	NMT 1.7
Nominal Volume	: 5.0 ml	
Extractable Volume	: 5.2 ml	NLT 5.0 ml
Specific gravity	: 1.152	(1.135 - 1.165)
pH	: 10.942	(10.5 - 11.1)
Absence of low molecular weight	:	
Iron [Fe(II) & FE(III)] Complex	: Complies	To comply
Turbidity	: 4.9	(4.4 -5.3)
Osmolarity	: 1252.45 mOsmol/L	(1150.0 - 1350.0) mOsmol/L
Alkalinity	: 0.6 ml of 0.1 N hydrochloric acid was consumed.	(0.5 - 0.8) ml of 0.1 N hydrochloric acid be consumed per ml of injection
Particulate matter	:	
Greater than or equal to 10 µm	: 255 Particles/Container	NMT 6000 Particles/Container
Greater than or equal to 25 µm	: 85 Particles/Container	NMT 600 Particles/Container
Limit of iron FE[(II)]	: 0.12 %	NMT 0.40 %

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiatē

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Iron sucrose injection USP	AR No.	: SA/GO-181225/015
Batch No.	: MPJ253642	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: USP	Date of Issue of the report	: 01/01/2026

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Brown coloured liquid filled in amber coloured glass ampoule.	
Content of chloride	: 0.015 %	(0.012 - 0.025) %
Bacterial Endotoxins	: Less than 3.7 USP EU/mg	NMT 3.7 USP EU/mg
Sterility	: Complies	To comply
Sucrose (By AAS)	: 301.41 mg/ml	(260 - 340) mg/ml
Leak test	: Complies	To comply

CONTENTS	OBTAINED	CLAIM	LIMITS
Assay:-			
Composition			
Ferric hydroxide in complex with sucrose			
eq. to elemental iron	20.31 mg	20.00 mg	(19.00 - 21.00) mg

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 01/01/2026

Surender Panghal
Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiatē Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiata

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiataresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Glimepiride Tablets IP 1 mg	AR No.	: SA/GO-181225/016
Batch No.	: 0065	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 25/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 26/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Light yellow coloured circular shaped biconvex uncoated tablet plain surface on both sides.	
Average weight	: 167.15 mg	
Uniformity of weight	: Min Max -1.26 % +2.63 %	Limit ±7.5 % of average weight To comply
Identification Test (By HPLC)	: Complies	To comply
Leak Test	: Complies	To comply
Hardness	: 3.5 kg/cm2	
Friability	: 0.12 %	NMT 0.1 %
Related substances (By HPLC)	:	
Glimepiride impurity B	: 0.26 %	NMT 2.50 %
Any other secondary impurity	: Not detected	NMT 0.50 %
Sum of all secondary impurities (Other than impurity B)	: 0.12 %	NMT 1.00 %
Sum of all secondary impurities	: 0.38 %	NMT 3.50 %
Dissolution test (By HPLC)	: Min Max Avg	Limit
In Phosphate buffer (pH 7.8)	: 89.32 % 94.46 % 92.87 %	Q. NLT 75.00 %
Uniformity of content (By HPLC)	: 96.82 % 101.63 % 99.17 %	
Acceptance value	: 3.5	NMT 15.0

CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By HPLC) :- Composition				
Each uncoated tablet contains :- Glimepiride IP	0.992 mg	1.00 mg	(0.90 - 1.10) mg	IP 2022

Disclaimer :

Satiata Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiat

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
E-mail: satiatresearch@gmail.com, Website : www.sratlabs.com

TEST REPORT



FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Glimepiride Tablets IP 1 mg	AR No.	: SA/GO-181225/016
Batch No.	: 0065	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 25/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 26/12/2025

In the opinion of the undersigned, the sample referred to above is of **Standard Quality** as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 26/12/2025


Person In-charge of Testing
Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Disclaimer :

Satiat Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.